Rosiglitazone may reduce thyroid cancer risk in patients with type 2 diabetes

Author： Tseng Chin-Hsiao  

Publisher： Informa Healthcare

ISSN： 0785-3890

Source： Annals of Medicine, Vol.45, Iss.8, 2013-12, pp. : 539-544

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Different Effects of Thiazolidinediones on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus: Pioglitazone vs Rosiglitazone

By  

Current Drug Safety, Vol. 5, Iss. 3, 2010-07 ,pp. : 234-244

Bentham Science Publishers

Access to resources Recommend Favorite

Cancer risk in patients with type 2 diabetes mellitus and their relatives

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 137, Iss. 4, 2015-08 ,pp. : 903-910

John Wiley & Sons Inc

Access to resources Recommend Favorite

Target intervention against multiple‐risk markers to reduce cardiovascular disease in patients with type 2 diabetes

By Gæde Peter   Pedersen Oluf  

Annals of Medicine, Vol. 36, Iss. 5, 2004-09 ,pp. : 355-366

Informa Healthcare

Access to resources Recommend Favorite

Impact of rosiglitazone therapy on the lipid profile, glycemic control, and medication costs among type 2 diabetes patients

By Suh Dong-Churl   Lee Dong-Hyun   McGuire Michael   Kim Chul-Min  

Current Medical Research and Opinion, Vol. 27, Iss. 8, 2011-08 ,pp. : 1623-1633

Informa Healthcare

Access to resources Recommend Favorite

Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US**

By Tunis Sandra L.   Minshall Michael E.   St. Charles Meaghan   Pandya Bhavik J.   Baran Robert W.  

Current Medical Research and Opinion, Vol. 24, Iss. 11, 2008-11 ,pp. : 3085-3096

Informa Healthcare

Access to resources Recommend Favorite